Table 2. Baseline and post-treatment CLSS grade, depressed volume due to lipoatrophy, and skin elasticity.
| Group | Baseline | Week 1 | Week 4 | Week 12 | Week 24 | P valuec | |
|---|---|---|---|---|---|---|---|
| CLSS grade | 2.24 ± 0.71 | 1.12 ± 0.32 | 1.20 ± 0.40 | 1.20 ± 0.40 | 1.28 ± 0.45 | < 0.001 | |
| Improvement rate, %a | - | 50 | 46.4 | 46.4 | 42.9 | ||
| P valued | - | < 0.001 | < 0.001 | < 0.001 | < 0.001 | ||
| Depressed volume, mm3 | 21.37 ± 20.67 | 14.20 ± 14.10 | 14.48 ± 14.45 | 15.54 ± 14.79 | 15.55 ± 15.11 | < 0.001 | |
| Improvement rate, %a | - | 32.9 | 31.2 | 26.1 | 25.4 | ||
| P valued | - | < 0.001 | < 0.001 | 0.002 | 0.001 | ||
| Skin elasticity, R2 | 0.62 ± 0.11 | 0.68 ± 0.14 | 0.63 ± 0.09 | 0.59 ± 0.10 | 0.63 ± 0.12 | 0.021 | |
| Improvement rate, %b | - | 9.3 | 1.0 | −4.5 | 1.6 | ||
| P valued | - | 0.033 | 0.677 | 0.101 | 0.623 | ||
Data are shown as mean ± SD. Statistically significant P values are in bold.
CLSS = Carruthers Lipoatrophy Severity Scale, R2 = percentage of viscoelasticity.
aDefined as (baseline measurement − follow-up measurement)/baseline measurement × 100%; bDefined as (follow-up measurement − baseline measurement)/baseline measurement × 100%; cRepeated measures analysis of variance, with the Greenhouse-Geisser correction. P < 0.05 was considered significant; dPost-hoc analysis of each time point with the Wilcoxon signed rank test with the Bonferroni correction, where P < 0.010 was considered significant.